Alongside the Phase 3 trial, which will be sponsored by GARDP
and the Drugs for Neglected Diseases initiative (DNDi), GARDP
will work with Entasis scientists to conduct non-clinical activities.
Jean-Pierre Paccaud, Director of Business Development at GARDP, Drugs for Neglected Diseases initiative (DNDi)
GARDP is a not-for-profit R&D organisation developing new treatments to tackle drug-resistant bacterial infections, and aiming at delivering them in a responsible, sustainable and accessible manner.